- Home
- CNFR vs NRXP Comparison
CNFR vs NRXP Comparison
Compare CNFR & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNFR
- NRXP
- Stock Information
- Founded
- CNFR 2009
- NRXP 2015
- Country
- CNFR United States
- NRXP United States
- Employees
- CNFR N/A
- NRXP N/A
- Industry
- CNFR Property-Casualty Insurers
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- CNFR Finance
- NRXP Health Care
- Exchange
- CNFR Nasdaq
- NRXP Nasdaq
- Market Cap
- CNFR 13.7M
- NRXP 48.5M
- IPO Year
- CNFR 2015
- NRXP N/A
- Fundamental
- Price
- CNFR $1.02
- NRXP $4.01
- Analyst Decision
- CNFR
- NRXP Strong Buy
- Analyst Count
- CNFR 0
- NRXP 3
- Target Price
- CNFR N/A
- NRXP $31.67
- AVG Volume (30 Days)
- CNFR 12.2K
- NRXP 2.8M
- Earning Date
- CNFR 11-13-2024
- NRXP 11-14-2024
- Dividend Yield
- CNFR N/A
- NRXP N/A
- EPS Growth
- CNFR N/A
- NRXP N/A
- EPS
- CNFR 2.40
- NRXP N/A
- Revenue
- CNFR $74,815,000.00
- NRXP N/A
- Revenue This Year
- CNFR N/A
- NRXP N/A
- Revenue Next Year
- CNFR $7.00
- NRXP N/A
- P/E Ratio
- CNFR $0.42
- NRXP N/A
- Revenue Growth
- CNFR N/A
- NRXP N/A
- 52 Week Low
- CNFR $0.65
- NRXP $1.10
- 52 Week High
- CNFR $1.91
- NRXP $7.33
- Technical
- Relative Strength Index (RSI)
- CNFR 41.56
- NRXP 61.48
- Support Level
- CNFR $0.98
- NRXP $3.20
- Resistance Level
- CNFR $1.06
- NRXP $6.01
- Average True Range (ATR)
- CNFR 0.08
- NRXP 0.95
- MACD
- CNFR -0.01
- NRXP 0.11
- Stochastic Oscillator
- CNFR 19.28
- NRXP 56.52
About CNFR Conifer Holdings Inc.
Conifer Holdings Inc is an insurance company engaged in the sale of property and casualty insurance products. It is engaged in three classes of insurance businesses namely commercial lines, personal lines, and wholesale agency business. Within these three businesses, the company offers various insurance products and insurance agency services. The company views the commercial and personal lines segments as underwriting business. The wholesale agency business provides non-risk bearing revenue through commissions and policy fees. Its revenues are derived from premiums earned from insurance operations.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.